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Background.D i ﬀerentiating branch duct from mixed intraductal papillary mucinous neoplasm (BD-IPMN) is problematic, but
clinically important as mixed IPMNs are managed surgically, while some BD-IPMN may be followed. Inﬂammatory mediator
proteins(IMPs)havebeenimplicatedinacuteandchronicinﬂammatoryandmalignantpancreaticdiseases.Aim.T oc ompar eIMP
proﬁle of pancreatic cyst ﬂuid collected endoscopically from BD-IPMN and mixed IPMN. Methods. Pancreatic cyst ﬂuid from ten
patients (5 BD-IPMN and 5 mixed IPMN) was collected by endoscopic ultrasound-guided ﬁne needle aspiration or endoscopic
retrograde cholangiopancreatography. Concentrations of 89 IMPs in these samples were determined using a multiplexed bead-
based microarray protein assay and compared between BD-IPMN and mixed IPMN. Results. Eighty-six of 89 IMPs were detected
in at least one of the 10 samples. Fourteen IMPs were detected only in mixed IPMN, while none were only in BD-IPMN. Of these,
TGF-β1wasmostprevalent,presentin3of5mixedIPMNs.Seventy-twoIMPsweredetectedinbothBD-IPMNandmixedIPMNs.
Of these, only G-CSF (P<0.05) was present in higher concentrations in mixed IPMNs. Conclusion.T G F - β1 and G-CSF detected
in endoscopically collected pancreatic cyst ﬂuid are potential diagnostic biomarkers capable of distinguishing mixed IPMN from
BD-IPMN.
1.Introduction
Many pancreatic cystic lesions have malignant potential,
includingbranchductandmixedintraductalpapillarymuci-
nous neoplasms (BD-IPMNs). As the malignant risk is sub-
stantially greater for mixed IPMN than BD-IPMN, current
management of mixed IPMN is surgical, while many BD-
IPMN may be managed conservatively. Therefore, accurately
distinguishing them has important clinical implications.
Diagnosis of these lesions relies mainly on the combination
of diagnostic imaging and analysis of cyst ﬂuid obtained
during endoscopic ultrasound-guided ﬁne needle aspiration
(EUS-FNA). While EUS-FNA is safe [1], the diagnostic accu-
racy of cytology, carcinoembryonic antigen (CEA), amylase,
andDN Amarkersfromcystﬂuidislimited[2,3].Traditional
biochemical cyst ﬂuid analysis generally requires 0.5–1mL of
cyst ﬂuid. Particularly for small pancreatic cysts, EUS-FNA
generally yields less than the essential minimum quantity,
which limits the ability to classify these lesions. Therefore,
better diagnostic biomarkers for pancreatic cystic lesions are
needed.
Diﬀerentially expressed inﬂammatory mediator proteins
(IMPs) may serve as diagnostic biomarkers for pancreatic
cystic neoplasms. IMPs, which include cytokines, chemo-
kines, and growth factors, are commonly associated with
acuteandchronicdiseasestates.Cytokines arelow molecular
weight regulatory proteins produced by various cell types
particularly during cellular stress events. Generally released2 Gastroenterology Research and Practice
in picomolar amounts, their concentration can increase over
1000-fold during physiological stress, such as trauma or
infection [4]. Chemokines are a superfamily of small chemo-
attractant cytokines (8–10kDa) which guide the migration
of cells via corresponding chemokine receptors [5]. These
proteins attract neutrophils, monocytes, and other circulat-
ing eﬀector cells to sites of infection or tissue damage [6].
Similartocytokines,manychemokinesareconsideredproin-
ﬂammatory. Other chemokines are considered homeostatic,
involved in controlling the migration of cells during normal
tissue maintenance or development [5].
The simultaneous analysis of numerous IMPs can be
performedinasingleexperimentwithasuspensionmicroar-
ray using IMP-speciﬁc capture antibodies coupled to color-
coded microspheres. Current IMP microarrays are both sen-
sitive to low concentrations of cytokines and amenable to
high-throughput analysis [7], making this technique ideal
for biomarker screening. Although the primary clinical use
of this technology is in the analysis of urine and blood,
microarray-based approaches may also be applied to proxi-
mal body ﬂuids, such as pancreatic cyst ﬂuid. We previously
performed an analogous IMP microarray-based analysis of
pancreatic ﬂuid collected during secretin-stimulated endo-
scopic pancreatic function testing to characterize IMPs in
chronic pancreatitis [8].
The primary objective of our exploratory investigation
is to compare IMP proﬁles in endoscopically collected pan-
creatic cyst ﬂuid aspirates of known BD-IPMN and mixed
IPMN using a multiplexed IMP-targeted microarray.
2.MaterialsandMethods
2.1. Study Population. The study was designed to analyze
IMPs in endoscopically collected pancreatic cyst ﬂuid using
a multiplexed suspension microarray assay in an academic
center. This protocol was approved by the Partners Institu-
tional Review Board. The study population included adult
patients referred to the Center for Pancreatic Diseases at
Brigham and Women’s Hospital for evaluation of pancreatic
cystic lesions. All subjects underwent the following: (1) com-
prehensive history and physical examination, (2) review of
radiologic data, and (3) EUS-FNA and/or endoscopic retro-
grade cholangiopancreatography (ERCP).
Only patients with diagnoses of BD-IPMN and mixed
IPMNwereincluded.Deﬁnitivediagnosiswasobtainedfrom
a combination of methodologies: a physician review of the
patient medical history with radiologic imaging, endoscopic
ﬁndings, and/or surgical pathology. A single abdominal
radiologist (NS), blinded to the oﬃcial radiology report,
reviewedtheradiologicstudies,whichincludedbothabdom-
inal computed tomography (CT) and magnetic resonance
cholangiopancreatography (MRCP). By radiology and/or
EUS, BD-IPMN was deﬁned as a unilocular or multilocu-
lated pancreatic cyst with smooth or loculated margins with
ademonstrablecommunication(shortneckorlongchannel)
to a nondilated main pancreatic duct [9, 10] (Figures 1(a)
and 1(b)). Absence of a discernable communication does
not exclude BD IPMN since the communication can be
diminutive or blocked by mucus and hence not visualized.
Mixed IPMN was deﬁned as a cystic lesion with ductal
communication and main pancreatic duct dilation greater
than or equal to 5mm (Figure 1(c)). Histologically, BD-
IPMN and mixed IPMN were deﬁned as a grossly visible,
noninvasive, mucin-producing papillary epithelial neoplasm
arising from the branch ducts or both branch and main
pancreatic ducts, respectively [11]. ERCP ﬁndings diagnostic
of at least main duct involvement in IPMN include the
presence of a “ﬁsh mouth papilla,” indicating the presence
of mucin within the main pancreatic duct and visualization
of a ﬁsh egg appearance in the main pancreatic duct during
pancreatoscopy [12].
2.2. Experimental Workﬂow. The overall analysis proceeded
as follows: (A) EUS-FNA or ERCP sample collection, (B)
particulate removal via centrifugation, (C) multiplexed IMP
microarray assays, and (D) statistical analysis of the resulting
proﬁles.
2.3. Endoscopic Ultrasound-Guided Fine Needle Aspira-
tion (EUS-FNA) and ERCP. Endosonography was per-
formed with a curvilinear echoendoscope (Olympus GF-
UC(T)140P-OL5; Olympus America Inc., Center Valley, PA)
using Aloka SSD-Alpha 5 and Alpha 10 (Olympus America
Inc., Center Valley, PA) processors. Curvilinear echoendo-
scopes are modiﬁed, oblique forward-viewing instruments
with curved linear ultrasound transducers providing real-
time visualization of the aspiration needle. In brief, after
obtaining informed consent and administration of intra-
venousconscioussedation,theechoendoscopewasadvanced
intotheuppergastrointestinaltract,thetargetlesionlocated,
and FNA of the cystic lesion performed using a 22-gauge
adjustable needle (EZ Shot, Olympus, Center Valley, PA).
Aspiratesweredividedintothreealiquotsfor(1)biochemical
analysisofCEAandamylase,(2)IMPassay,and(3)cytologic
evaluation with ﬂuid placed into Cytolyt preservative (Cytyc,
Boxborough, MA). Samples were stored at −80◦C until
IMP analysis (see Section 2.4). Antibiotic prophylaxis was
administered during the procedure and for 3 days following
the procedure.
The ERCP procedure proceeded in a similar manner to
EUS with the exception of using a duodenoscope (Olympus
TJF-160VF; Olympus America Inc., Center Valley, PA) and
cannula (Tandem XL M00535700; Boston Scientiﬁc, Natick,
MA) to cannulate the pancreatic duct. Pancreatic duct ﬂuid
was aspirated through the cannula and samples sent for
analyses.
2.4. Pancreatic Cyst Fluid IMP Microarray Analysis. As u s -
pension microarray assay was used to measure the concen-
t r a t i o no f8 9I M P si np a n c r e a t i cc y s tﬂ u i ds a m p l e sf r o m
10 individuals. We selected this 89-cytokine panel as it
was the most comprehensive panel available at the time of
this study. A list of the IMPs investigated with their cor-
responding abbreviations is provided in Supplementary
Table 1 available online at doi:10.1155/2012/247309. Unlike
mass spectrometry-based proteomic assays of pancreatic
ﬂuids [13–16], suspension microarray assays require only
minimal sample preparation of centrifugation to removeGastroenterology Research and Practice 3
(a) (b)
(c)
Figure 1: Imaging of BD-IPMN and mixed IPMN. (a) MRI of BD-IPMN: arrow points to communication between BD-IPMN and normal
main pancreatic duct. (b) EUS of BD-IPMN: arrow points to communication between cyst and main pancreatic duct. (c) MRI of mixed
IPMN: arrow points to diﬀusely massively dilated main pancreatic duct.
particulates. Immediately following ﬂuid collection, samples
werealiquotedinto1.5mLmicrotubesandcentrifugedonan
Eppendorf centrifuge 5415R at 4◦C and 10,000×gt or e m o v e
particulates.Thesupernatantwastransferredintoanewtube
a n ds t o r e da t−80◦C prior to analysis.
Immediately prior to the microarray analysis, the con-
centration of known standards was determined by a 5-
parameter logistic regression algorithm with analysis of the
medianﬂuorescenceintensityreadingsonan8-pointprotein
standard curve. This procedure ensured that the reading
was within the linear range of the assay. The ﬂuorescence
intensity values of the standards were treated as unknowns,
and the concentration of each standard was calculated using
the derived regression equation. The ratio of the calculated
value to the expected value of this standard was determined.
A ratio between 70 and 130% for each standard indicated a
good ﬁt. If ﬂuorescence intensity values of samples plateaued
or were outside the range of standard curves, a retest
with diluted samples was performed to ensure that the
ﬂuorescence intensity measurement of unknown samples fell
inside the linear range of standard curves.
Levels of IMPs in cyst ﬂuid were determined using
microsphere-based suspension microarray technology
(AssayGate, Ijamsville, MD) [17]. The microarray analysis
was performed according to previously published methods
[18–20]. In brief, multiple analytes in a single aliquot (75μL)
of pancreatic ﬂuid were simultaneously quantiﬁed with
Bio-Plex 200 Bead Reader System (Bio-Rad, Hercules, CA).
Microparticles were conjugated previously to diﬀering con-
centrations of two ﬂuorophores to generate distinct bead
sets. Each bead set was coated with a capture antibody
speciﬁc for one analyte. Captured analyte was detected
using a biotinylated detection antibody and streptavidin-
phycoerythrin conjugate. The bead analyzer was a dual
laser, ﬂow-based, sorting, and detection platform. One laser
was bead speciﬁc and determined which analyte was being
detected. The second laser determined the magnitude of
phycoerythrin-derived signal, which is directly proportional4 Gastroenterology Research and Practice
to the amount of analyte bound. No more than 75μLo f
pancreaticcystﬂuidwasusedforeachassay,andeachsample
was tested in duplicate.
2.5. Statistical Analysis. IMP concentrations were expressed
in picograms per milliliter (pg/mL) of pancreatic cyst ﬂuid
and analyzed by the Kruskal-Wallis one-way analysis of
variance by a rank test for two samples using SAS 9.2 (Cary,
NC). A P value < 0.05 was considered statistically signiﬁcant.
For the purpose of this exploratory analysis, a P value <
0.1 was considered a trend warranting further investigation.
The Bonferroni or Benjamini-Hochberg correction method
is generally used to account for multiple testing of collected
samples, but was not used in our study as it is not required
for exploratory data analysis [21].
3. Results
3.1. Patient Characteristics. The demographics and clinical
characteristics of the 10 study subjects are shown in Table 1.
Pancreatic cyst ﬂuid was safely collected via EUS-FNA (n =
10) and ERCP (n = 1) from all subjects. Five patients
had asymptomatic BD-IPMN with the ﬁnal diagnosis made
by surgical pathology in three patients and radiology in
two patients. These patients both had MRCP demonstrating
communication of a nondilated main pancreatic duct with
the cyst. The nondilated pancreatic duct was conﬁrmed
by EUS in both patients. One patient with mixed IPMN
presented with acute pancreatitis. Final diagnosis of mixed
IPMN was determined by pathology in four patients and
radiology in one patient who refused surgery. The latter
patient had a diﬀusely dilated main pancreatic duct to 7mm
with communication of the cystic lesion to this pancreatic
duct seen on MRCP and EUS. As expected, amylase and CEA
concentrations were not signiﬁcantly diﬀerent between BD-
IPMN and mixed IPMN samples.
3.2. Protein Microarray Assay Detected IMPs in All Ten Pan-
creatic Cyst Fluid Samples. The concentration of IMPs rang-
ed from below the limit of detection to greater than
15,000pg/mL, and several IMPs had median concentrations
above >1000pg/mL. In the BD-IPMN samples, ENA-78 and
NAP2 were detected with median concentrations greater
than 1000pg/mL. Similarly in the mixed IPMN samples,
HCC1, ICAM1, MIF, NAP2, PDGF-AA, and SCGF-B had
median concentrations greater than 1000pg/mL. Figure 2
summarizes the proteins detected in the BD-IPMN and
mixed IPMN samples. Fourteen proteins were identiﬁed
only in mixed IPMN ﬂuid, while none of the assayed IMPs
were solely found in BD-IPMN samples. In addition, 72 of
the 89 IMPs assayed were present in both types of cysts
(Supplementary Table 2), while 3 IMPs (b-NGF, IL-11 and
IL-29) were not detected in either cohorts.
3.3. Fourteen IMPs Were Detected Only in Mixed IPMN Fluid
Aspirates (Table 2). The following IMPs were all present in
mixedIPMNandnotdetectedinBD-IPMNsamples:eotaxin
3, GM-CSF, I-309, IL-5, IL-9, IL-17, lymphotactin, TGF-
β1, TGF-β2, TGF-β3, TNF-β,S C F ,T P O ,a n dT S L P .T h e
07 21 4
BD-IPMN
Eotaxin-3
GM-CSF
I-309
IL-5
IL-9
IL-17
Lymphotactin
SCF
TPO
TSLP
Mixed IPMN
TNF-β
TGF-β1
TGF-β2
TGF-β3
Figure 2:VenndiagramofIMPsidentiﬁedinBD-IPMNandmixed
IPMN. IMPs detected only in mixed IPMN are listed to the right of
the diagram. Of the 89 IMPs assayed, three were not detected in
either types of cyst (b-NGF, IL-11 and IL-29).
concentrations of these IMPs in individual mixed IPMN
samples ranged from 0.5 to 170.7pg/mL. The majority of
these IMPs was detected in one or two samples. TGF-β1,
however, was identiﬁed in 3 samples. No IMPs were detected
only in BD-IPMN cyst ﬂuid.
3.4. Three IMPs Were Present in Higher Concentrations in
Mixed IPMN Fluid Aspirates (Supplementary Table 2 and
Figure 3). Among the 72 IMPs detected in both BD-IPMN
and mixed IPMN samples, G-CSF (P<0.05), IL-23 (P<
0.1), and VCAM-1 (P<0.1) had higher concentrations
in mixed IPMN compared to BD-IPMN samples. None
of the 72 proteins found in both BD-IPMN and mixed
IPMN samples had signiﬁcantly higher concentrations in
BD-IPMN ﬂuid samples.
4. Discussion
We identiﬁed IMPs with a microsphere-based suspension
protein microarray assay in all endoscopically obtained
pancreatic cyst ﬂuid samples from patients with BD-IPMN
and mixed IPMN. Our study diﬀerentiated the IMP proﬁles
of BD-IPMN and mixed IPMN ﬂuid aspirates. Speciﬁcally,
we identiﬁed a total of 17 IMPs from the 89 tested that
were diﬀerentially expressed between BD-IPMN and mixed
IPMN. Fourteen IMPs were detected only in mixed IPMN,
while three IMPs were present in higher concentrations in
mixed IPMN.
Accurate diﬀerentiation between BD-IPMN and mixed
IPMN has important clinical implications. Mixed IPMN
harbors a risk of malignancy up to 50–70%, similar to main
duct IPMN (MD-IPMN), compared to approximately 15–
25% for BD-IPMN; therefore, current guidelines recom-
mend surgical resection of mixed IPMN [22]. In contrast,
many BD-IPMN, including small ones without suspicious
radiologic features, may be managed conservatively [22].
DiﬀerentiatingMD-IPMNfromBD-IPMNbyradiologiccri-
teria is clearly deﬁned in the recent International AssociationGastroenterology Research and Practice 5
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Figure 3: Box and whisker plots of diﬀerentially expressed IMPs between BD-IPMN and mixed IPMN. (a) G-CSF, P value < 0.05, (b) IL-23,
and (c) VCAM-1, P values < 0.1. Bottom and top edges of box at 25th and 75th percentiles, respectively. Horizontal line within box marks
50th percentile (median). Whiskers extend from box as far as data extend, at most 1.5 interquartile ranges. Outlier represented by “x”.
of Pancreatology guidelines [23] while mixed IPMN may be
more diﬃcult to separate from BD-IPMN [24]. Therefore,
we focused our study on diﬀerentiating BD-IPMN from
mixed IPMN as additional tools are needed to accurately
classify IPMNs. We believe the IMPs we have identiﬁed
diﬀerentiating mixed IPMN from BD-IPMN merit further
investigation as potential biomarkers of pancreatic cystic
neoplasms.
Cytokine and chemokine production is closely linked to
pancreatic stellate cell function, particularly in the patho-
genesis of pancreatic cancer [25–28]. Pancreatic stellate cells
express growth factors, chemokines, and cytokines known
to participate in inﬂammatory and ﬁbrotic responses to
pancreatic injury [25, 29–34]. These responses are often pre-
cursors to the development of malignant and pre-malignant
lesions [35–38]. The expressed cytokines and chemokinesGastroenterology Research and Practice 7
Table 2: Inﬂammatory mediator proteins (n = 14) detected only in mixed IPMN.
Cytokine
Mixed IPMN
Concentration, pg/mL
Samples Median IQR
M1 M2 M3 M4 M5
Eotaxin-3 N.D. 91.2 11.8 N.D. N.D. 51.5 39.7
GM-CSF N.D. 127.5 9.3 N.D. N.D. 68.4 59.1
I-309 N.D. 2.4 2.0 N.D. N.D. 2.2 0.2
IL-5 N.D. 11.7 0.5 N.D. N.D. 6.1 5.6
IL-9 N.D. 14.2 N.D. N.D. N.D. 14.2 0.0
IL-17 N.D. 15.7 6.7 N.D. N.D. 11.2 4.5
Lymphotactin N.D. N.D. N.D. N.D. 37.2 37.2 0.0
SCF N.D. 6.4 2.3 N.D. N.D. 4.3 2.1
TGF-β1 N.D. 104.3 94.5 N.D. 81.2 94.5 11.5
TGF-β2 N.D. 170.7 41.4 N.D. N.D. 106.0 64.7
TGF-β3 N.D. 14.7 N.D. N.D. N.D. 14.7 0.0
TNF-β N.D. 3.8 8.6 N.D. N.D. 6.2 2.4
TPO N.D. 76.7 26.7 N.D. N.D. 51.7 25.0
TSLP N.D. 6.3 N.D. N.D. N.D. 6.3 0.0
IQR: interquartile range; N.D.: not detected.
controlling the cellular functions of pancreatic stellate cells
representpotentialdiagnosticandtherapeutictargets,several
of which have been identiﬁed in our current analysis of
pancreatic cyst ﬂuid, collected primarily by EUS-FNA.
The TGF-β family, in particular TGF-β1, is the most
promising potential biomarker for mixed IPMN, as it was
detected in three of the ﬁve mixed IPMN samples and none
of the BD-IPMN samples. TGF-β is a family of proteins that
control proliferation, diﬀerentiation, and other functions in
most cells [39]. It plays a role in immunity and cancer by
arresting the cell cycle at the G1 stage to stop proliferation,
induce diﬀerentiation, and/or promote apoptosis [40]. The
TGF-β family consists of three members with similar peptide
structures(TGF-β1,TGF-β2,andTGF-β3),allthreeofwhich
were identiﬁed only in mixed IPMN samples. Interestingly,
multiple studies have demonstrated an association between
TGF-β and pancreatic cancer [41–48]. In addition, TGF-
β signals through SMAD4, a critical tumor suppressor
inactivated in half of pancreatic cancers [49].
G-CSF, IL-23, and VCAM-1 had higher expression levels
in mixed IPMN compared to BD-IPMN and also rep-
resent potential diagnostic biomarkers. Additionally, these
cytokines may lead to insights into the oncogenic nature
of these pancreatic cystic neoplasms. Pancreatic cancer has
been associated with elevated serum G-CSF [50, 51]a n d
G-CSF positive immunohistochemistry [52]. G-CSF shares
proinﬂammatory properties with IL-23, which we also
measured in higher concentration in mixed IPMN [53]. IL-
23 is produced by macrophages and thus has a role in the
inﬂammatory response to infection and can promote tumor
genesis and growth [54]. VCAM-1 mediates the adhesion
of eosinophils, lymphocytes, monocytes, and basophils to
vascular endothelium [55] and has been shown to be
upregulated in pancreatic disease [56]; however, its role in
mixed IPMN and cancer remains unclear.
Our results demonstrate the applicability of IMP analysis
in diﬀerentiating mixed IPMN from BD-IPMN, but must
be validated further in larger studies. IMP proﬁle compar-
isons with other clinically relevant pancreatic cystic lesions,
including mucinous cystic neoplasms and serous cystade-
nomas, is needed and will expand the diagnostic utility
of this technique. A potential limitation is that the peak
concentration of certain IMPs in pancreatic cyst ﬂuid may
depend on the degree of dysplasia in the cyst. Assessing IMP
levels in pancreatic cysts with diﬀerent grades of dysplasia
merits further study. In addition, one of our patients with
mixed IPMN had a history of acute pancreatitis, which can
have an eﬀect on the IMP levels in the pancreatic ﬂuid. The
larger size of pancreatic cysts in the mixed IPMN may have
aﬀected IMP levels as well, and this needs further study.
In conclusion, we have successfully identiﬁed diﬀeren-
tially expressed IMPs in pancreatic cyst ﬂuid of BD-IPMN
compared with mixed IPMN using endoscopic collection
methods in tandem with cytokine microarray technology.
Withfurthervalidation,ourﬁndingsmayenabletheaccurate
diﬀerentiation of mixed IPMN from BD-IPMN using a
diagnostic cytokine panel. The advantages of directly investi-
gating pancreatic cyst ﬂuid with this microarray technology
include high speciﬁcity, small sample volume requirement,
cost eﬀectiveness, and complementarity to other detection
methods, such as mass spectrometry, ELISA, and western
blotting [57]. Further investigation of other pancreatic cystic
neoplasms, as well as the diﬀerent degrees of dysplasia
in various pancreatic cysts, using the methods described
herein may generate major insights into cytokine-mediated
pathogenesis of pancreatic cancer.8 Gastroenterology Research and Practice
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